I-FDA ivuma i-Keytruda pembrolizumab njenge-lineotherapy yokuqala yomhlaza kumhlaza ongqongqo

Olu lulwamkelo lweziyobisi lwe-9th lwe-FDA oluxhaswe yi-Stand Up to Cancer research.

I-FDA kutshanje ivumile ichiza le-immunotherapy pembrolizumab njengonyango lonyango lokuqala kwizigulana ezineentlobo ezithile ze Umhlaza ogqithileyo wemibala. Olu luvavanyo lwe-9th lwe-FDA oluxhaswe luphando lwe-Stand Up to Cancer® (SU2C).

Izigulana ezisandula ukufumanisa ukuba zine advanced okanye metastatic microsatellite ukungazinzi-okuphezulu (MSI-H) or Ukungalunganga kokulungiswa okungalunganga (dMMR) umhlaza wolusu Ngaphambili ibiya kumiselwa i-pembrolizumab kuphela emva kokunyanga okunyanga okusemgangathweni.

I-FDA yamkele i-pembrolizumab, ekwabizwa ngokuba iphantsi kwegama lophawu Isitshixo, njengonyango lodidi lokuqala lwe- I-metastatic MSI-H-dMMR yomhlaza wolusu ngokusekwe kwiziphumo zokuqala ezivela kuvavanyo lwesigaba sesithathu sonyango, olwaluxhaswe ngokuyinxenye sisibonelelo seSU2C.

"Xa kuthelekiswa nonyango lwendabuko, i-pembrolizumab yayiphezulu kunye neziphumo ebezingalindelekanga ezimbalwa ze-MSI-H-dMMR yezigulana ezinamacala," utshilo uLuis A. Diaz, MD, iNtloko yeCandelo leSolid Tumor Oncology kwiSikhumbuzo seSikhumbuzo seCancer Kettering Cancer kunye nenkokheli ye Iqela lePhupha leCancer Coral Coral, olwaqhuba uphando. "Kukho eminye imihlaza yomhlaza eqinileyo kubantu abadala nakubantwana abanezi ngxaki ze-MSI-H-dMMR, ngoko ke uphando lwethu lunokuba nolwazelelo ngezinye iintlobo zomhlaza."

Ngokujikeleze i-4-5% yamathumba omhlaza we-metastatic ane-MSI-H-dMMR biomarkers, ezibangelwa kukungakwazi kweeseli ukulungisa iimpazamo ezenziwe ngexesha lenkqubo yokwahlula iiselula kwaye kunokukhokelela kuphuhliso lwethumba ngakumbi.

Uphononongo lubandakanya i-307 MSI-H-dMMR yezigulana ezinomhlaza kumazwe angama-23 anyangwa nge-pembrolizumab okanye i-chemotherapy esemgangathweni. Iithagethi zePembrolizumab kunye neebhloko zeproteni ebizwa ngokuba yi-PD-1 enokuthintela iiseli zomzimba ezibizwa ngokuba zii-T cell ekupheliseni iiseli zomhlaza ngokufanelekileyo.

Ugqirha Diaz kunye neqela lakhe bafumanise ukuba abaguli abanomhlaza we-MSI-H-dMMR baphathwa nge-pembrolizumab khange babone ukuba umhlaza wabo usasazekile kwiinyanga eziyi-16.5, xa kuthelekiswa nezigulana ezanyangwa nge-chemotherapy esemgangathweni ezabona amathumba abo ekhula emva kweenyanga eziyi-8.2. Izigulana ezifumana ichemotherapy esemgangathweni nayo ineziphumo ebezingalindelekanga ezibi kunezigulana ezifumana ipembrolizumab. Iziphumo zokufunda ezizeleyo za papashwa kwiNew England Journal of Medicine ngoDisemba 2, 2020.

"I-Stand Up To Cancer Colorectal Dream Cancer Team inegalelo elibonakalayo kunyango oluphuculweyo lwe-MSI-H-dMMR yezigulana ezilulamileyo," utshilo owaphumelela uNobel uPhillip A. Sharp, PhD, usihlalo we-Stand Up To Cancer's Scientific Advisory Committee kunye Unjingalwazi weziko kwiZiko likaDavid H. Koch loPhando oluHlanganisiweyo loMhlaza eMassachusetts Institute of Technology. "Lo ngumzekelo obalaseleyo wokuba imodeli yophando yokusebenzisana yomhlaza inefuthe elithe ngqo kubomi bezigulana ezinomhlaza."

Umhlaza ongathandabuzekiyo ngu Okwesibini oonobangela bokufa komhlaza phakathi kwamadoda nabasetyhini baseMelika badibene kwaye baphantse 148,000 baseMerika Uza kufumana uxilongo olutsha lomhlaza wekolon okanye we-rectal ngo-2020. Ngelixa amazinga okufa komhlaza obukhaliphileyo ehle kakhulu ngenxa yokonyuka kokuvavanywa nokuphuculwa konyango, 1 kwabathathu abadala abaneminyaka engama-3 okanye ngaphezulu musa ukufumana ukuhlolwa okucetyiswayo. Amatyala amatsha omhlaza ongalunganga ezenzeka ngezinga lokukhula phakathi kwabantu abadala abancinci nabaphakathi e-US, kunye nenani lamatyala omhlaza ongalunganga kubantu abangaphantsi kwama-50 kulindeleke ukuba baphinde kabini yi 2030.

Njengoko umhlaza ongathandabuzekiyo uyaqhubeka nokuchaphazela ngokungafaniyo abantu ngombala
(Abantu abamnyama banamazinga aphezulu yomhlaza ongalunganga walo naluphi na uhlanga okanye uhlanga e-US), ukuphuculwa kovavanyo kunye nokuchaneka okutsha kunye nonyango ekujolise kulo kufuneka kufikelele kuzo zonke izigulana. I-SU2C ibhengeze i-Initiative Equity Initiative ngoJanuwari 2020. Eli nyathelo lifuna onke amaqela exesha elizayo afuna u-Stand Up ukuya kwi-Cancer inkxaso-mali yokujongana nokufunwa nokugcinwa kwezigulana ezivela kubuhlanga obahlukeneyo kunye namaqela obuhlanga kunye noluntu olungasetyenziswanga ukuphucula inxaxheba eyahlukeneyo kwizilingo zeklinikhi. Eli nyathelo likwabandakanya ukusebenzisana namaqela abhengeziyo kunye nomzi mveliso kunye nabaxhasi benkampani ukuhambisa uphando kunye neenzame zokwazisa uluntu phambili.

Iqela le-SU2C Colorectal Cancer Dream Team lilawulwa yi-Stand Up To Cancer iqabane lezesayensi, i Umbutho waseMelika woPhando lweCancer.

UMirabai Vogt-James
310-739-5576